Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

This post focuses on these five incidents and reveals the security blind spots in AI technology applications through timeline backtracking ... environment such as Amazon Bedrock, Google Cloud Vertex ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Google has confirmed the recent loss of Timeline data from the Maps app due to technical issues. Thankfully, users will be able to get the data back, provided they have backed it up beforehand.

But it's logical to ask: What's Vertex's long-term story? Where will the company be in 10 years, for example? Let's find out. First, a bit of background on Vertex's CF program since it's so ...

Thankfully, the issue doesn’t seem to be impacting everyone – the Google Maps timeline on our devices appears to be fine, for example – but this is nevertheless frustrating. While having ...

Have you suddenly found that your Google Maps Timeline has vanished? Well, you’re not alone. There have been countless reports of Timelines vanishing, and it’s not clear if this is a temporary ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Many have reported that years of travel records have disappeared. This happens even when Timeline settings are on. When they check Google Maps, they see the message: “No visits for this day.” ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...